Company Overview
Check-Cap Ltd. operates as a clinical stage medical diagnostics company that specializes in developing and commercializing capsule-based screening technology products designed to advance non-invasive diagnostic capabilities. The entity functions within the broader Healthcare sector, specifically targeting the Diagnostics & Research industry, where innovation in screening methodologies is critical for improving patient outcomes and reducing procedural risks. As of the latest available data, the company possesses a market capitalization of $11.95 million, though specific annual revenue figures are not disclosed in the current reporting period, and the total employee count is listed as N/A. The combination of a market cap under $12 million and the absence of reported revenue indicates that Check-Cap Ltd. remains a small-cap entity with limited market penetration, suggesting that the firm is likely still in a phase of product development or early commercialization rather than mature revenue generation.
Financial Health
The company reports negative financial performance across its core profitability metrics, with a net income loss of $-13,624,000 for the trailing twelve months and an EBITDA of $-3,756,500, while revenue figures are not currently disclosed. The substantial disparity between the reported net income loss and the less severe EBITDA loss reveals a significant cost structure burden related to interest expenses or other financing costs that erode operating earnings before reaching the bottom line. Free cash flow stands at $-1,058,125, indicating a continuous outflow of capital that constrains the company's financial flexibility and limits its ability to fund operations without external financing. All three margin metrics—gross margin, operating margin, and profit margin—are recorded at 0.0%, which suggests that the company has not yet generated positive gross profitability or operating leverage, likely due to high initial research and development expenditures or costs associated with bringing capsule-based products to market. Regarding balance sheet strength, the company holds $1.42 million in cash against a debt obligation of $139,000, resulting in a debt-to-equity ratio of 3.69, which implies a highly leveraged capital structure relative to its equity base. Despite the low absolute debt amount, the high debt-to-equity ratio indicates that the company relies heavily on equity financing or has minimal retained earnings to support its obligations. Liquidity is constrained further by a current ratio of 0.71, which signals that the company's current assets are insufficient to cover its current liabilities, creating potential short-term liquidity pressures. Finally, the return on equity is -130.1% and the return on assets is -20.8%, metrics that reveal management is currently destroying shareholder value and utilizing assets inefficiently to generate returns.
Valuation Assessment
The trailing twelve-month P/E ratio and forward P/E ratio are both listed as N/A, reflecting the fact that the company has negative earnings and therefore cannot be valued using traditional earnings-based multiples. In the absence of a trailing P/E, the price-to-book ratio becomes a primary valuation metric, standing at 2.55, which indicates that the market values the company's equity at a significant premium over its net book value. Alternative valuation metrics such as price-to-sales and EV/EBITDA provide further insight, where the price-to-sales ratio is N/A and the EV/EBITDA is -2.21, suggesting that investors are pricing the stock based on asset value or potential rather than current earnings power or sales multiple. The stock price has exhibited considerable volatility over the past year, ranging from a 52-week low of $0.59 to a 52-week high of $3.92. Based on the 52-week high and low provided, the current trading position sits within a wide range, having experienced a total expansion of approximately 564% from the lowest point to the highest point during the measurement period. The beta value is 0.82, which indicates that the stock's price volatility is slightly lower than the broader market benchmark, suggesting the asset may be less sensitive to general market fluctuations than the average large-cap stock.
Growth & Income
Revenue growth year-over-year and earnings growth year-over-year are both recorded as N/A, meaning that historical growth rates cannot be calculated from the current dataset due to the absence of prior comparable periods or revenue disclosure. Because there are no disclosed growth rates to compare, it is impossible to determine whether earnings are growing faster or slower than revenue, as both metrics lack positive values. The company does not pay a dividend, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, which means the firm reinvests all available capital, including its cash reserves, back into research, development, and operational scaling rather than distributing income to shareholders. This strategy is typical for clinical stage companies that prioritize funding their capsule-based technology roadmap over providing immediate income to investors. The overall growth and income profile is characterized by a complete lack of current profitability, no dividend distribution, and a reliance on cash reserves and equity markets to sustain operations while pursuing long-term product milestones.